Novartis Institutes For Biomedical Research President Mark Fishman: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Fishman discusses his take on how metabolic drug development will change in the future, challenges in developing RNAi-based treatments and the role of federally funded research in innovation.
You may also be interested in...
Novartis Institutes For Biomedical Research President Mark Fishman: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Head of firm’s research arm discusses Novartis’ drug discovery model, a growing pipeline of biologics and the company’s partnering strategy.
Galvus “Approvable” Letter Requests Additional Study In Renal Failure Patients
Analysts indicate approval of the type 2 diabetes therapy could be delayed for a year or more.
Alnylam Seeks Deals As RNAi Interest Heats Up
Company looking to build on current deals with Merck and Novartis, COO says in interview with "The Pink Sheet" DAILY.